SCP.F Scancell Holdings plc

Healthcare Biotechnology Frankfurt Exchange
0.0760 EUR
Close of Nov 13, 2026
0.7200 2.90
Market cap
EUR 10.3M
P/E
-
P/B
7.38x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Apr 2026.

Is SCP.F undervalued?

Graham number

The Graham number of Scancell Holdings plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Scancell Holdings plc fundamental analysis

No fundamental analysis for Scancell Holdings plc yet.

Scancell Holdings plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Scancell Holdings plc

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. The company's product candidates include ImmunoBody, DNA active immunotherapies encode a protein in the form of a modified antibody; Moditope, a potent peptide active immunotherapy targeting tumour-specific neoantigens through the MHC-II presentation pathway; SCIB1 which is in phase I for adjuvant melanoma; SCIB1/iSCI…

Full company profile